BR112018001707A2 - agonistas de receptor 5-ht2c e composições e métodos de uso - Google Patents
agonistas de receptor 5-ht2c e composições e métodos de usoInfo
- Publication number
- BR112018001707A2 BR112018001707A2 BR112018001707A BR112018001707A BR112018001707A2 BR 112018001707 A2 BR112018001707 A2 BR 112018001707A2 BR 112018001707 A BR112018001707 A BR 112018001707A BR 112018001707 A BR112018001707 A BR 112018001707A BR 112018001707 A2 BR112018001707 A2 BR 112018001707A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- addiction
- disease
- sleep
- antipsychotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199382P | 2015-07-31 | 2015-07-31 | |
| PCT/US2016/044426 WO2017023679A1 (en) | 2015-07-31 | 2016-07-28 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018001707A2 true BR112018001707A2 (pt) | 2018-09-18 |
Family
ID=56684262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018001707A BR112018001707A2 (pt) | 2015-07-31 | 2016-07-28 | agonistas de receptor 5-ht2c e composições e métodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10272094B2 (enExample) |
| EP (1) | EP3328835B1 (enExample) |
| JP (1) | JP6789578B2 (enExample) |
| KR (1) | KR20180031035A (enExample) |
| CN (1) | CN108137508B (enExample) |
| AU (1) | AU2016302755B2 (enExample) |
| BR (1) | BR112018001707A2 (enExample) |
| CA (1) | CA3002525A1 (enExample) |
| EA (1) | EA039412B1 (enExample) |
| HK (1) | HK1255850A1 (enExample) |
| IL (1) | IL257107B (enExample) |
| MA (1) | MA42527A (enExample) |
| MX (1) | MX375045B (enExample) |
| WO (1) | WO2017023679A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016302755B2 (en) * | 2015-07-31 | 2020-09-10 | Arena Pharmaceuticals, Inc. | 5-HT2C receptor agonists and compositions and methods of use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110668951B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 一种盐酸司来吉兰的合成工艺 |
| AU2020258086A1 (en) | 2019-04-17 | 2021-11-11 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20220410894A1 (en) * | 2021-06-29 | 2022-12-29 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
| EP4416027A1 (en) | 2021-10-14 | 2024-08-21 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| WO1992018005A1 (en) | 1991-04-16 | 1992-10-29 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CN1805939B (zh) * | 2003-06-17 | 2010-10-13 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关病症的苯并氮杂卓衍生物 |
| AU2004282101A1 (en) * | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
| EP2510949A4 (en) * | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| US9556200B2 (en) * | 2012-03-06 | 2017-01-31 | Takeda Pharmaceutical Company Limited | Tricyclic compound |
| AR092568A1 (es) * | 2012-09-14 | 2015-04-22 | Abbvie Deutschland | Derivados triciclicos de quinolinas y de quinoxalinas |
| AU2016302755B2 (en) | 2015-07-31 | 2020-09-10 | Arena Pharmaceuticals, Inc. | 5-HT2C receptor agonists and compositions and methods of use |
-
2016
- 2016-07-28 AU AU2016302755A patent/AU2016302755B2/en not_active Ceased
- 2016-07-28 BR BR112018001707A patent/BR112018001707A2/pt active Search and Examination
- 2016-07-28 MX MX2018001380A patent/MX375045B/es active IP Right Grant
- 2016-07-28 MA MA042527A patent/MA42527A/fr unknown
- 2016-07-28 JP JP2018504658A patent/JP6789578B2/ja not_active Expired - Fee Related
- 2016-07-28 KR KR1020187005698A patent/KR20180031035A/ko not_active Withdrawn
- 2016-07-28 EA EA201890402A patent/EA039412B1/ru unknown
- 2016-07-28 CN CN201680058247.6A patent/CN108137508B/zh not_active Expired - Fee Related
- 2016-07-28 CA CA3002525A patent/CA3002525A1/en not_active Abandoned
- 2016-07-28 WO PCT/US2016/044426 patent/WO2017023679A1/en not_active Ceased
- 2016-07-28 HK HK18114926.0A patent/HK1255850A1/zh unknown
- 2016-07-28 US US15/748,205 patent/US10272094B2/en active Active
- 2016-07-28 EP EP16751083.3A patent/EP3328835B1/en active Active
-
2018
- 2018-01-23 IL IL257107A patent/IL257107B/en active IP Right Grant
-
2019
- 2019-03-12 US US16/299,880 patent/US10624900B2/en active Active
-
2020
- 2020-04-14 US US16/848,013 patent/US11395824B2/en active Active
-
2022
- 2022-06-10 US US17/837,622 patent/US20230055376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN108137508A (zh) | 2018-06-08 |
| IL257107A (en) | 2018-03-29 |
| US11395824B2 (en) | 2022-07-26 |
| CA3002525A1 (en) | 2017-02-09 |
| US20180214455A1 (en) | 2018-08-02 |
| US20200383993A1 (en) | 2020-12-10 |
| AU2016302755A1 (en) | 2018-03-15 |
| HK1255850A1 (zh) | 2019-08-30 |
| MX2018001380A (es) | 2018-06-15 |
| US20230055376A1 (en) | 2023-02-23 |
| EA201890402A1 (ru) | 2018-09-28 |
| IL257107B (en) | 2021-03-25 |
| EP3328835A1 (en) | 2018-06-06 |
| US10272094B2 (en) | 2019-04-30 |
| CN108137508B (zh) | 2021-08-27 |
| MX375045B (es) | 2025-03-06 |
| JP6789578B2 (ja) | 2020-11-25 |
| WO2017023679A1 (en) | 2017-02-09 |
| AU2016302755B2 (en) | 2020-09-10 |
| US20200078368A1 (en) | 2020-03-12 |
| US10624900B2 (en) | 2020-04-21 |
| NZ739883A (en) | 2021-03-26 |
| EP3328835B1 (en) | 2022-10-12 |
| JP2018522025A (ja) | 2018-08-09 |
| EA039412B1 (ru) | 2022-01-25 |
| KR20180031035A (ko) | 2018-03-27 |
| MA42527A (fr) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018001707A2 (pt) | agonistas de receptor 5-ht2c e composições e métodos de uso | |
| BR112017023088A2 (pt) | agonistas do receptor 5-ht2c e composições e métodos de uso | |
| BR112019003142A2 (pt) | agonistas do receptor 5-ht2c, composições e métodos de uso | |
| EA201000006A1 (ru) | Способы и композиции для лечения аллергических заболеваний | |
| EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
| TN2011000463A1 (en) | Composition and methods for increasing muscle growth | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| MX2020007765A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| EA201200002A1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
| BR112018006016A2 (pt) | intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga | |
| EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
| NO20082167L (no) | Anti-Myostatin-antistoffer | |
| EA201790267A1 (ru) | Новые модуляторы киназ | |
| EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
| EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| TN2014000513A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| LT2013015A (lt) | Farmacinės kompozicijos | |
| EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| DE602005021696D1 (de) | Indazolcarbonsäureamidverbindungen | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen | |
| AR098271A1 (es) | Agonistas del receptor 5-ht₂c | |
| ATE529514T1 (de) | Sirna zur hemmung der il-6-expression und diese enthaltende zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |